| Literature DB >> 30046046 |
Ezgi Eyluel Bankoglu1, Charlotte Arnold1, Ilona Hering2, Mohammed Hankir3, Florian Seyfried2, Helga Stopper4.
Abstract
The number of bariatric surgeries being performed worldwide has markedly risen. While the improvement in obesity-associated comorbidities after bariatric surgery is well-established, very little is known about its impact on cancer risk. The peripheral lymphocyte micronucleus test is a widely used method for the monitoring of chromosomal damage levels in vivo, and micronucleus frequency positively correlates with cancer risk. Therefore, the aim of this study was to compare the micronucleus frequency before and after bariatric surgery in obese subjects. Peripheral blood mononuclear cells were collected from 45 obese subjects before and at two time-points after bariatric surgery (6 and 12 months) to assess spontaneous micronucleus frequency. Consistent with the increased cancer risk previously shown, bariatric surgery-induced weight loss led to a significant reduction in lymphocyte micronucleus frequency after 12 months. Interestingly, comorbidities such as type 2 diabetes mellitus and metabolic syndrome further seemed to have an impact on the lymphocyte micronucleus frequency. Our findings may indicate a successful reduction of cancer risk in patients following weight loss caused by bariatric surgery.Entities:
Mesh:
Year: 2018 PMID: 30046046 PMCID: PMC6060147 DOI: 10.1038/s41598-018-29581-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Body weight, BMI and weight loss before and after bariatric surgery. (A) Body weight in kg, (B) Body Mass Index (BMI kg/m2), (C) Weight loss in kg and (D) Weight reduction in %. Before surgery, n = 45; 6 M, n = 35; 12 M, n = 45. *p ≤ 0.05 significant vs. Before and °p ≤ 0.05 significant vs. 6 M.
Summary for body weight, BMI, age and gender before and after surgery.
| Groups | Body weight (kg) | BMI (kg/m2) | Age | Gender |
|---|---|---|---|---|
| Before | 142.55 ± 3.07 | 51.02 ± 0.94 | 44.37 ± 1.62 | Female: 38 Male: 7 |
| 6 M | 113.06 ± 2.74 | 40.76 ± 0.92 | — | — |
| 12 M | 103.14 ± 3.09 | 37.11 ± 1.04 | — | — |
Biochemical blood parameters.
| Parameters | Before | After 6 months | After 12 months | Significance |
|---|---|---|---|---|
| Glucose (mg/dl) | 99.14 ± 3.90 | 86.52 ± 3.61 | 94.50 ± 5.22 | *,# |
| Alkaline phosphatase (U/l) | 80.14 ± 5.41 | 82.07 ± 4.06 | 75.60 ± 3.53 | ∆ |
| Triglyceride (mg/dl) | 139.61 ± 10.44 | 110.82 ± 5.50 | 105.24 ± 7.22 | *,# |
| Cholesterol (mg/dl) | 190.12 ± 7.11 | 180.27 ± 6.26 (N = 44) | 178.93 ± 6.73 | *,# |
| LDL (mg/dl) | 114.15 ± 6.84 | 105.93 ± 5.75 | 97.67 ± 6.09 | *,#,∆ |
| HDL (mg/dl) | 48.12 ± 9.86 | 52.23 ± 1.56 | 59.62 ± 2.07 | #,∆ |
| CRP (mg/dl) | 1.18 ± 0.18 | 0.59 ± 0.09 | 0.54 ± 0.11 | *,#,∆ |
| HbA1c (%) | 5.94 ± 0.18 | 5.42 ± 0.08 | 5.45 ± 0.11 | *,# |
LDL: low density lipoprotein, HDL: high density lipoprotein, CRP: C-reactive protein and HbA1c: glycated hemoglobin *p ≤ 0.05 Before vs. After 6 months, #p ≤ 0.05 Before vs. After 12 months and ∆p ≤ 0.05 After 6 months vs. After 12 months.
Comorbidities before surgery.
| Comorbidities | Number | % |
|---|---|---|
| IR | 14/45 | 31.1 |
| T2DM | 13/45 | 28.9 |
| IDDM | 6/45 | 13.3 |
| NASH/NAFLD | 40/45 | 88.9 |
| Hypertension | 30/45 | 66.7 |
| Metabolic syndrome | 14/45 | 31.1 |
IR: insulin resistance, T2DM: type 2 diabetes mellitus, IDDM: insulin dependent diabetes mellitus, NASH: non-alcoholic steatohepatitis, NAFLD: non-alcoholic fatty liver disease.
Figure 2Micronucleus frequency per mill (%o) in isolated lymphocytes of obese subjects. (A) Representative picture of a micronucleus in a binucleated cell indicated by the white arrow. (B) Micronucleus frequency per mill (%o) before and after surgery. Before, n = 45; 6 M, n = 35 and 12 M, n = 45. *p ≤ 0.05 significant vs. before.
Proliferation Index (PI), Mitosis and Apoptosis.
| Groups | PI | Mitosis (%o) | Apoptosis (%o) |
|---|---|---|---|
| Before | 1.52 ± 0.03 | 12.87 ± 1.34 | 9.60 ± 1.47 |
| 6 M | 1.60 ± 0.03 | 20.81 ± 1.74 (*) | 6.77 ± 1.02 |
| 12 M | 1.59 ± 0.03 (#) | 18.88 ± 1.23 (#) | 5.63 ± 1.21 (#) |
*p ≤ 0.05 Before vs. After 6 months and #p ≤ 0.05 Before vs. After 12 months.
Figure 3Micronucleus frequency per mill (%o) among the subgroups of obese subjects before surgery. (A) Comparison of micronucleus frequency between all patients, nondiabetic (ND), IR/T2DM, nonhypertensive (NH), hypertensive (H), nonmetabolic syndrome (NMetS) and metabolic syndrome (MetS). (B) Comparison of micronucleus frequency between IR/T2DM, hypertensive (H) and metabolic syndrome (MetS) before and after surgery. (C) Comparison of micronucleus frequency between a subgroup of HbA1c < 6 and HbA1c ≥ 6 before and after surgery. Before surgery, nAll = 45, nND = 19, nIR/T2DM = 26, nNH = 16, nH = 29, nNMetS = 31 and nMetS = 14; 6 M, nIR/T2DM = 21, nH = 21, and nMetS = 10; 12 M, nIR/T2DM = 26, nH = 29 and nMetS = 14. *p ≤ 0.05 significant vs. All or vs. BeforeIR/T2DM or vs. BeforeMetS, #p ≤ 0.05 significant vs. ND or vs. BeforeHbA1c≥6 and op ≤ 0.05 significant vs. NMetS.